Holen Sie sich die Stockscreener-App
1.25
1.63%
0.02
Handel nachbörslich:
1.23
-0.02
-1.60%
Schlusskurs vom Vortag:
$1.23
Offen:
$1.24
24-Stunden-Volumen:
34,616
Relative Volume:
0.19
Marktkapitalisierung:
$3.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.08M
KGV:
-0.1947
EPS:
-6.42
Netto-Cashflow:
$-11.56M
1W Leistung:
+0.81%
1M Leistung:
+1.63%
6M Leistung:
-78.63%
1J Leistung:
-84.91%
1-Tages-Spanne:
$1.23
$1.26
1-Wochen-Bereich:
$1.19
$1.32
52-Wochen-Spanne:
$1.01
$11.55
Enveric Biosciences Inc Stock (ENVB) Company Profile
Firmenname
Enveric Biosciences Inc
Sektor
Branche
Telefon
239-302-1707
Adresse
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
Vergleichen Sie ENVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.25 | 3.16M | 0 | -15.08M | -11.56M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Enveric Biosciences Inc Aktie (ENVB) Neueste Nachrichten
Enveric Biosciences Announces Participation in 2025 BIO International Convention | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Participation in 2025 BIO International Convention - Business Wire
Enveric Biosciences Receives Notice Of Allowance For New Class Of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders - MarketScreener
Enveric Biosciences Receives Notice of Allowance for New Class o - GuruFocus
Enveric Biosciences (ENVB) Gains Patent Approval for Innovative Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders | ENVB Stock News - GuruFocus
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders - Yahoo Finance
Enveric Receives U.S. Patent for Sleep, CNS Therapeutics - Insider Monkey
Enveric’s Patent Win Targets New Frontiers in Sleep Medicine - microdose.buzz
Enveric Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Enveric Biosciences (ENVB) Secures Patent for Novel CNS Therapeu - GuruFocus
Enveric Biosciences Receives New US Patent on Molecules for Central Nervous System, Sleep Therapeutics - marketscreener.com
Enveric Biosciences secures patent for sleep disorder molecules By Investing.com - Investing.com Nigeria
Enveric Biosciences (ENVB) Secures Patent for Novel CNS Therapeutic Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds - Yahoo Finance
Enveric Biosciences announces results from EB-003 trial - Yahoo Finance
Enveric’s EB-003 shows statistically significant improvements in model of severe chronic depression - BioWorld MedTech
Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003 - marketscreener.com
Enveric Biosciences reports breakthrough in depression model By Investing.com - Investing.com India
Enveric Biosciences (ENVB) Reports Promising Preclinical Results - GuruFocus
Enveric Biosciences reports breakthrough in depression model - Investing.com Australia
Enveric Biosciences (ENVB) Reports Promising Preclinical Results for EB-003 | ENVB Stock News - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 | ENVB Stock News - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ:ENVB) Stock Price Down 0.8% – Here’s Why - Defense World
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease - marketscreener.com
Enveric Biosciences Stakes Its Claim in Neurodegeneration Market - microdose.buzz
Enveric Biosciences files provisional patent for new molecules By Investing.com - Investing.com Canada
Enveric Biosciences Identifies Neuroplastogen Candidates with Po - GuruFocus
Enveric Biosciences (ENVB) Explores New Path with Neurodegenerative Drug Patent | ENVB Stock News - GuruFocus
Enveric Biosciences files new provisional patent application - TipRanks
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results - BioSpace
Enveric Biosciences Reports First Quarter 2025 Financial and Cor - GuruFocus
Enveric Biosciences (ENVB) Projected to Post Earnings on Tuesday - Defense World
Enveric Biosciences stock plummets after pricing $5M capital raise - MSN
Enveric Biosciences (NASDAQ:ENVB) Trading Down 1% – Here’s Why - Defense World
Enveric Biosciences appoints new accounting firm - Investing.com India
Enveric Biosciences appoints new accounting firm By Investing.com - Investing.com South Africa
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges - Investing.com Canada
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges By Investing.com - Investing.com South Africa
Psychedelic: Enveric, Filament Health report earnings results - TipRanks
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 - BioSpace
Enveric posts $9.5M loss for 2024, but revenue could be on horizon with licensing deals - Green Market Report
Enveric Lands Massive $184M Biotech Licensing Deals as EB-003 Shows Promise - Stock Titan
Enveric Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Enveric Biosciences, Inc. SEC 10-K Report - TradingView
Enveric Biosciences Inc. (ENVB) reports earnings - qz.com
Enveric Biosciences Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Finanzdaten der Enveric Biosciences Inc-Aktie (ENVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):